Innate Pharma S.A. (IPH.PA)
EUR 1.98
(-3.37%)
EUR 1.98
(-3.37%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 184.19 Million EUR | -11.39% |
| 2022 | 207.86 Million EUR | -22.29% |
| 2021 | 267.49 Million EUR | -12.99% |
| 2020 | 307.42 Million EUR | -23.4% |
| 2019 | 401.36 Million EUR | -11.05% |
| 2018 | 451.21 Million EUR | 76.93% |
| 2017 | 255.02 Million EUR | -9.43% |
| 2016 | 281.57 Million EUR | -7.97% |
| 2015 | 305.95 Million EUR | 237.36% |
| 2014 | 90.69 Million EUR | 62.29% |
| 2013 | 55.88 Million EUR | 15.71% |
| 2012 | 48.29 Million EUR | -19.65% |
| 2011 | 60.1 Million EUR | 25.2% |
| 2010 | 48.01 Million EUR | -25.24% |
| 2009 | 64.21 Million EUR | 5.52% |
| 2008 | 60.86 Million EUR | -3.63% |
| 2007 | 63.15 Million EUR | -8.81% |
| 2006 | 69.25 Million EUR | 179.63% |
| 2005 | 24.76 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 151.49 Million EUR | -17.75% |
| 2024 Q2 | 151.49 Million EUR | 0.0% |
| 2023 Q3 | 184.19 Million EUR | -7.46% |
| 2023 Q4 | 184.19 Million EUR | 0.0% |
| 2023 FY | 184.19 Million EUR | -11.39% |
| 2023 Q1 | 199.04 Million EUR | -4.24% |
| 2023 Q2 | 199.04 Million EUR | 0.0% |
| 2022 Q2 | 280.43 Million EUR | 0.0% |
| 2022 Q1 | 280.43 Million EUR | 4.84% |
| 2022 FY | 207.86 Million EUR | -22.29% |
| 2022 Q4 | 207.86 Million EUR | 0.0% |
| 2022 Q3 | 207.86 Million EUR | -25.88% |
| 2021 Q4 | 267.49 Million EUR | 0.0% |
| 2021 Q2 | 266.21 Million EUR | 0.0% |
| 2021 Q1 | 266.21 Million EUR | -13.4% |
| 2021 FY | 267.49 Million EUR | -12.99% |
| 2021 Q3 | 267.49 Million EUR | 0.48% |
| 2020 Q1 | 333.06 Million EUR | -17.02% |
| 2020 FY | 307.42 Million EUR | -23.4% |
| 2020 Q4 | 307.42 Million EUR | 0.0% |
| 2020 Q3 | 307.42 Million EUR | -7.7% |
| 2020 Q2 | 333.06 Million EUR | 0.0% |
| 2019 Q2 | 352.55 Million EUR | 0.0% |
| 2019 Q3 | 401.36 Million EUR | 13.84% |
| 2019 Q4 | 401.36 Million EUR | 0.0% |
| 2019 Q1 | 352.55 Million EUR | -21.87% |
| 2019 FY | 401.36 Million EUR | -11.05% |
| 2018 FY | 451.21 Million EUR | 76.93% |
| 2018 Q4 | 451.21 Million EUR | 0.0% |
| 2018 Q3 | 451.21 Million EUR | 99.73% |
| 2018 Q2 | 225.91 Million EUR | 0.0% |
| 2018 Q1 | 225.91 Million EUR | -11.41% |
| 2017 FY | 255.02 Million EUR | -9.43% |
| 2017 Q1 | 246.38 Million EUR | -12.5% |
| 2017 Q2 | 246.38 Million EUR | 0.0% |
| 2017 Q4 | 255.02 Million EUR | 0.0% |
| 2017 Q3 | 255.02 Million EUR | 3.51% |
| 2016 Q3 | 281.57 Million EUR | -0.28% |
| 2016 FY | 281.57 Million EUR | -7.97% |
| 2016 Q4 | 281.57 Million EUR | 0.0% |
| 2016 Q2 | 282.35 Million EUR | 0.0% |
| 2016 Q1 | 282.35 Million EUR | -7.71% |
| 2015 FY | 305.95 Million EUR | 237.36% |
| 2015 Q2 | 305.08 Million EUR | 0.0% |
| 2015 Q3 | 305.95 Million EUR | 0.29% |
| 2015 Q4 | 305.95 Million EUR | 0.0% |
| 2015 Q1 | 305.08 Million EUR | 236.4% |
| 2014 Q3 | 90.69 Million EUR | -12.35% |
| 2014 FY | 90.69 Million EUR | 62.29% |
| 2014 Q4 | 90.69 Million EUR | 0.0% |
| 2014 Q1 | 103.46 Million EUR | 85.15% |
| 2014 Q2 | 103.46 Million EUR | 0.0% |
| 2013 Q3 | 55.88 Million EUR | 33.63% |
| 2013 FY | 55.88 Million EUR | 15.71% |
| 2013 Q1 | 41.82 Million EUR | -13.41% |
| 2013 Q2 | 41.82 Million EUR | 0.0% |
| 2013 Q4 | 55.88 Million EUR | 0.0% |
| 2012 Q3 | 48.29 Million EUR | -13.48% |
| 2012 FY | 48.29 Million EUR | -19.65% |
| 2012 Q4 | 48.29 Million EUR | 0.0% |
| 2012 Q2 | 55.81 Million EUR | 0.0% |
| 2011 Q4 | 60.1 Million EUR | 0.0% |
| 2011 FY | 60.1 Million EUR | 25.2% |
| 2011 Q2 | 41.47 Million EUR | 0.0% |
| 2010 FY | 48.01 Million EUR | -25.24% |
| 2010 Q2 | 55.29 Million EUR | 0.0% |
| 2010 Q4 | 48.01 Million EUR | 0.0% |
| 2009 Q4 | 64.21 Million EUR | 0.0% |
| 2009 FY | 64.21 Million EUR | 5.52% |
| 2008 FY | 60.86 Million EUR | -3.63% |
| 2007 FY | 63.15 Million EUR | -8.81% |
| 2006 FY | 69.25 Million EUR | 179.63% |
| 2005 FY | 24.76 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -1152.162% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 43.683% |
| Adocia SA | 24.95 Million EUR | -638.071% |
| Aelis Farma SA | 26.28 Million EUR | -600.86% |
| Biophytis S.A. | 11.93 Million EUR | -1443.172% |
| Advicenne S.A. | 12.4 Million EUR | -1384.589% |
| genOway Société anonyme | 31.84 Million EUR | -478.453% |
| IntegraGen SA | 8 Million EUR | -2202.311% |
| Medesis Pharma S.A. | 1.92 Million EUR | -9461.836% |
| Neovacs S.A. | 47.53 Million EUR | -287.501% |
| NFL Biosciences SA | 3.97 Million EUR | -4538.888% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -1135.123% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -4816.046% |
| Sensorion SA | 46.49 Million EUR | -296.164% |
| Theranexus Société Anonyme | 7.23 Million EUR | -2444.898% |
| TME Pharma N.V. | 2.49 Million EUR | -7294.34% |
| Valbiotis SA | 33.24 Million EUR | -453.997% |
| TheraVet SA | 7.53 Million EUR | -2344.762% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | -422.178% |
| argenx SE | 4.11 Billion EUR | 95.521% |
| BioSenic S.A. | 9.55 Million EUR | -1826.907% |
| Celyad Oncology SA | 16.28 Million EUR | -1031.268% |
| DBV Technologies S.A. | 165.65 Million USD | -11.194% |
| Galapagos NV | 4.35 Billion EUR | 95.773% |
| Genfit S.A. | 173.87 Million EUR | -5.936% |
| GeNeuro SA | 6.31 Million EUR | -2817.724% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | -286.303% |
| Inventiva S.A. | 69.13 Million EUR | -166.41% |
| MaaT Pharma SA | 42.93 Million EUR | -329.044% |
| MedinCell S.A. | 36.94 Million EUR | -398.52% |
| Nanobiotix S.A. | 93.89 Million EUR | -96.165% |
| Onward Medical N.V. | 43.62 Million EUR | -322.18% |
| Oryzon Genomics S.A. | 106.9 Million EUR | -72.304% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | -124.9% |
| Oxurion NV | 6.55 Million EUR | -2712.107% |
| Pharming Group N.V. | 426.33 Million EUR | 56.797% |
| Poxel S.A. | 4.82 Million EUR | -3719.055% |
| GenSight Biologics S.A. | 9.08 Million EUR | -1926.995% |
| Transgene SA | 45.21 Million EUR | -307.353% |
| Financière de Tubize SA | 1.92 Billion EUR | 90.408% |
| UCB SA | 15.53 Billion EUR | 98.815% |
| Valneva SE | 469.39 Million EUR | 60.759% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | -497.467% |